...
首页> 外文期刊>Philosophical Transactions of the Royal Society of London, Series B. Biological Sciences >Peptide aptamers: tools to negatively or positively modulate HSPB1(27) function
【24h】

Peptide aptamers: tools to negatively or positively modulate HSPB1(27) function

机译:肽适体:负或正调节HSPB1(27)功能的工具

获取原文
获取原文并翻译 | 示例

摘要

Human HSP27 (HSPB1) is a molecular chaperone sensor which, through dynamic changes in its phosphorylation and oligomerization, allows cells to adapt to changes in their physiology and/or mount a protective response to injuries. In pathological conditions, the high level of HSPB1 expression can either be beneficial, such as in diseases characterized by cellular degenerations, or be malignant in cancer cells where it promotes tumourigenesis, metastasis and anti-cancer drug resistance. Structural changes allow HSPB1 to interact with specific client protein partners in order to modulate their folding/activity and/or half-life. Therefore, the search is open for therapeutic compounds aimed at either down- or upregulating HSPB1 activity. In this respect, we have previously described two peptide aptamers (PA11 and PA50) that specifically interact with HSPB1 small oligomers and decrease its anti-apoptotic and tumourigenic activities. A novel analysis of the different HSPB1-interacting aptamers that were isolated earlier revealed that one aptamer (PA23) has the intriguing ability to stimulate the protective activity of HSPB1. We show here that this aptamer abolishes the dominant negative effect induced by the R120G mutant of aB-crystallin (HSPB5) by disrupting its interaction with HSPB1. Hence, developing structure-based interfering strategies could lead to the discovery of HSPB1-based therapeutic drugs.
机译:人类HSP27(HSPB1)是一种分子伴侣传感器,通过其磷酸化和寡聚化的动态变化,使细胞能够适应其生理变化和/或对损伤进行保护。在病理条件下,高水平的HSPB1表达可能是有益的(例如在以细胞变性为特征的疾病中),或者在癌细胞中是恶性的,在癌细胞中它促进肿瘤发生,转移和抗癌药物耐药性。结构变化使HSPB1与特定的客户蛋白质伴侣相互作用,从而调节其折叠/活性和/或半衰期。因此,对旨在下调或上调HSPB1活性的治疗性化合物的研究是开放的。在这方面,我们先前已经描述了两种肽适体(PA11和PA50),它们与HSPB1小寡聚体特异性相互作用,并降低其抗凋亡和致瘤活性。对较早分离的与HSPB1相互作用的不同适体的新颖分析表明,一个适体(PA23)具有刺激HSPB1保护活性的吸引人的能力。我们在这里显示,该适体通过破坏其与HSPB1的相互作用,消除了aB-晶状蛋白(HSPB5)的R120G突变体诱导的显性负作用。因此,开发基于结构的干扰策略可能会导致发现基于HSPB1的治疗药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号